Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
30701 | 134 | 52.1 | 92% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
151 | 22214 | IMMUNOTHERAPY//DENDRITIC CELLS//CANCER IMMUNOLOGY IMMUNOTHERAPY |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | MRNA DELIVERY | Author keyword | 6 | 100% | 3% | 4 |
2 | MRNA TRANSFECTION | Author keyword | 4 | 33% | 7% | 9 |
3 | RIBOL | Address | 3 | 100% | 2% | 3 |
4 | MRNA VACCINE | Author keyword | 3 | 60% | 2% | 3 |
5 | TRANSLAT EXPT ONCOL | Address | 3 | 42% | 4% | 5 |
6 | RNACTIVE | Author keyword | 2 | 67% | 1% | 2 |
7 | TRANSLAT ONCOL IMMUNOL TRON | Address | 2 | 67% | 1% | 2 |
8 | MODIFIED MRNA | Author keyword | 1 | 100% | 1% | 2 |
9 | SAM VACCINE | Author keyword | 1 | 100% | 1% | 2 |
10 | DNA FREE | Author keyword | 1 | 50% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | MRNA DELIVERY | 6 | 100% | 3% | 4 | Search MRNA+DELIVERY | Search MRNA+DELIVERY |
2 | MRNA TRANSFECTION | 4 | 33% | 7% | 9 | Search MRNA+TRANSFECTION | Search MRNA+TRANSFECTION |
3 | MRNA VACCINE | 3 | 60% | 2% | 3 | Search MRNA+VACCINE | Search MRNA+VACCINE |
4 | RNACTIVE | 2 | 67% | 1% | 2 | Search RNACTIVE | Search RNACTIVE |
5 | MODIFIED MRNA | 1 | 100% | 1% | 2 | Search MODIFIED+MRNA | Search MODIFIED+MRNA |
6 | SAM VACCINE | 1 | 100% | 1% | 2 | Search SAM+VACCINE | Search SAM+VACCINE |
7 | DNA FREE | 1 | 50% | 1% | 1 | Search DNA+FREE | Search DNA+FREE |
8 | FUSOKINE | 1 | 50% | 1% | 1 | Search FUSOKINE | Search FUSOKINE |
9 | GENETIC IMMUNOPOTENTIATION | 1 | 50% | 1% | 1 | Search GENETIC+IMMUNOPOTENTIATION | Search GENETIC+IMMUNOPOTENTIATION |
10 | GL67 | 1 | 50% | 1% | 1 | Search GL67 | Search GL67 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | VACCINATION TRIAL | 11 | 69% | 7% | 9 |
2 | ANTIGEN ENCODING RNA | 3 | 100% | 2% | 3 |
3 | ELECTROPORATED DENDRITIC CELLS | 3 | 45% | 4% | 5 |
4 | REVERSE CAP ANALOGS | 3 | 42% | 4% | 5 |
5 | ALPHAVIRUS REPLICON | 2 | 67% | 1% | 2 |
6 | ALPHAVIRUS VECTORS | 1 | 25% | 4% | 5 |
7 | RNA BASED VACCINES | 1 | 50% | 1% | 2 |
8 | SELF REPLICATIVE RNA | 1 | 100% | 1% | 2 |
9 | SYNTHETIC GENE DELIVERY | 1 | 50% | 1% | 2 |
10 | TRANSFECTED DENDRITIC CELLS | 1 | 10% | 8% | 11 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
A novel, disruptive vaccination technology Self-adjuvanted RNActive (R) vaccines | 2013 | 10 | 29 | 59% |
RNA-based vaccines | 2012 | 20 | 62 | 39% |
Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines | 2014 | 4 | 103 | 34% |
mRNA-based therapeutics - developing a new class of drugs | 2014 | 9 | 223 | 19% |
Challenges and advances towards the rational design of mRNA vaccines | 2013 | 5 | 49 | 43% |
RNA: The new revolution in nucleic acid vaccines | 2013 | 10 | 111 | 31% |
Tumor vaccination using messenger RNA: prospects of a future therapy | 2011 | 28 | 50 | 32% |
Messenger RNA (mRNA) nanoparticle tumour vaccination | 2014 | 2 | 89 | 27% |
Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles | 2014 | 4 | 81 | 20% |
Developing mRNA-vaccine technologies | 2012 | 11 | 140 | 24% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | RIBOL | 3 | 100% | 2.2% | 3 |
2 | TRANSLAT EXPT ONCOL | 3 | 42% | 3.7% | 5 |
3 | TRANSLAT ONCOL IMMUNOL TRON | 2 | 67% | 1.5% | 2 |
4 | PARTNERSTANDORT TUBINGEN | 1 | 50% | 0.7% | 1 |
5 | PEDIAT PEDIAT INFECTIOL IMMUNOL 1 | 1 | 50% | 0.7% | 1 |
6 | TUMOR IMMUNOL GRP TIGR | 1 | 50% | 0.7% | 1 |
7 | GHENT GRP NANOMED | 1 | 13% | 3.0% | 4 |
8 | UMR INSERM CNRS U1052 5286 | 0 | 33% | 0.7% | 1 |
9 | TRON TRANSLAT ONCOL | 0 | 13% | 2.2% | 3 |
10 | CELL MOL BIOL MED | 0 | 14% | 1.5% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000200250 | DENDRITIC CELLS//DENDRITIC CELL//TUMOR LYSATE |
2 | 0.0000154616 | DNA VACCINE//DNA VACCINES//DNA IMMUNIZATION |
3 | 0.0000106321 | EIF4E//EIF 4E//CAPPING EFFICIENCY |
4 | 0.0000103662 | BIKDD//MITOCHONDRIAL CYTOCHROME C RELEASE//BAX OVEREXPRESSION |
5 | 0.0000096910 | UNC93B1//MARY KIRKLAND LUPUS//TLR7 |
6 | 0.0000095782 | CATIONIC LIPID//CATIONIC LIPIDS//CATIONIC LIPOSOME |
7 | 0.0000095076 | GENE MED GRP//GENEMED GRP//EXPT TREATMENT CYST FIBROSIS |
8 | 0.0000082792 | ALPHAVIRUS//SEMLIKI FOREST VIRUS//SINDBIS VIRUS |
9 | 0.0000069217 | PHOTOCHEMICAL INTERNALIZATION//PHOTOCHEMICAL INTERNALISATION//CANC STEM CELL INNOVAT SFI CAST |
10 | 0.0000067027 | CHIMERIC ANTIGEN RECEPTOR//ADOPTIVE CELL THERAPY//CHIMERIC IMMUNE RECEPTOR |